Get in touch for more information about AAV

Our understanding of AAV is increasing

AAV (ANCA-associated vasculitis) is a group of progressive, rare, severe autoimmune diseases.1,2

AAV can affect blood vessels in different parts of the body resulting in damage to vital organs such as the lungs, kidneys, nervous system, gastrointestinal system, skin, eyes, and heart2

Read more

ERA-EDTA
Discover the latest clinical data in AAV
Our new HCP Dialogue tool is now available

Recent updates

EULAR 2021

Scientific session recordings highlighting the challenges of balancing clinical priorities in ANCA-associated vasculitis.

node.label

'Mind the gap –
balancing remission and risk of relapse in AAV'

node.label

'Striking the right balance in AAV'

node.label

'The future of remission maintenance in AAV:
new mechanisms, new approaches'

ERA-EDTA 2021

Scientific session recording focusing on the reality of remission and relapse aswell as recent clinical evidence regarding glucocorticoids and impact on patient experience.

node.label

'Striking the right balance in AAV'

Kidney week – American Society of Nephrology 2020 (virtual)

Renal disease during maintenance treatment in ANCA associated vasculitis (AAV) remains a problem and glucocorticoid use is high

Poster

Country differences exist in the treatment of ANCA associated vasculitis (AAV) but high dose and prolonged glucocorticoid use is observed across Europe

Poster

German Congress of Rheumatology 2020

Maintenance treatment for ANCA-associated vasculitis (AAV) in real world practice in Germany - reality of vasculitis remission, relapse and burden of disease.

Poster

Rare Revolution Magazine – Special edition

The latest edition of Rare Revolution Magazine is dedicated exclusively to ANCA-associated vasculitis. Rare Revolution is a digital magazine giving a voice to patients affected by RARE conditions and the charities that represent and support them – you can view the May edition here.

WCN 2020

Real world clinical outcomes in ANCA associated vasculitis (AAV) – unmet needs in achieving and sustaining remission and avoiding cumulative organ damage.

Abstract Poster

Interactive tools

Use our interactive educational tools to discover more about ANCA-associated vasculitis (AAV).

AAV World is a brand-new educational game that sheds light on the clinical priorities in AAV in a fun and interactive way. Take part in AAV World and test your skills through a mix of challenges, brainteasers, riddles and quizzes. Or why not join the Rare Disease Investigation Team and put your expertise to the test in our mysterious challenge.

Complete the challenges

 

AAV Mechanism of Disease

See how the interaction between neutrophils and the alternative complement system are at the heart of the vasculitis process in AAV.

More information

 

Patient videos

Introduction to AAV

AAV is a rare, severe small vessel vasculitis that affects multiple organs and has a high acute mortality risk1

Disease mechanism

The interaction between the activated alternative complement pathway, neutrophils and C5a is at the heart of vasculitic damage in AAV2

Treatment guidelines

A framework of practice for the treatment and management of AAV patients3

Treatment outcomes

Treatment has improved, but treatment-related complications remain common

Interactive tools

Use our interactive educational tools to discover more about AAV

References & footnotes

Congress calendar

ERA-EDTA

19-22 May

EULAR

1-4 June

ASN

4-7 November 2021

ACR

5-9 November 2021

20th International Vasculitis and ANCA workshop

3-6 April 2022

Useful sources

EUVAS

European vasculitis society website

Read more
EULAR treatment recommendations

EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis

Read more

Additional Resources

EULAR 2021

Scientific session recordings highlighting the challenges of balancing clinical priorities in ANCA-associated vasculitis.

EULAR 2021

'Mind the gap –
balancing remission and risk of relapse in AAV'

EULAR 2021

'Striking the right balance in AAV'

EULAR 2021

'The future of remission maintenance in AAV:
new mechanisms, new approaches'

ERA-EDTA 2021

Scientific session recording focusing on the reality of remission and relapse aswell as recent clinical evidence regarding glucocorticoids and impact on patient experience.

ERA-EDTA 2021

'Striking the right balance in AAV'

Kidney week – American Society of Nephrology 2020 (virtual)

Renal disease during maintenance treatment in ANCA associated vasculitis (AAV) remains a problem and glucocorticoid use is high

Poster

Country differences exist in the treatment of ANCA associated vasculitis (AAV) but high dose and prolonged glucocorticoid use is observed across Europe

Poster

German Congress of Rheumatology 2020

Maintenance treatment for ANCA-associated vasculitis (AAV) in real world practice in Germany - reality of vasculitis remission, relapse and burden of disease.

Poster

ERA-EDTA 2020

Significant burden of disease during maintenance treatment of ANCA-associated vasculitis (AAV) patients in real world practice in Europe.

Poster

EULAR 2020

Maintenance treatment for ANCA-associated vasculitis in real world practise in Europe – reality of vasculitis remission and relapse and significant burden of disease.

Presentation

Patterns of drug treatment for maintenance phase of ANCA-associated vasculitis (AAV) in real world practise in Europe – prolonged glucocorticoid use is common and various treatment regimes are used.

Poster

WCN 2020

Real world clinical outcomes in ANCA associated vasculitis (AAV) – unmet needs in achieving and sustaining remission and avoiding cumulative organ damage.

Abstract Poster

Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Achieving and Sustaining Remission while Reducing Organ Damage

Interviews with Three Key Opinion Leaders

European Medical Journal article

Vasculitis UK newsletter

Newsletter

ASN 2019

Glucocorticoids for Remission Induction in Incident ANCA-Associated Vasculitis (AAV) Patients in Real-World Practice: High Exposure and Temporal Relationship to Adverse Events

Abstract Poster

Maintenance Treatment in ANCA-Associated Vasculitis (AAV): Definition, Clinical Outcomes, and Significant Burden of Disease in Real-World Clinical Practice

Abstract Poster

ERA-EDTA 2019

Adverse events and infections as major concerns with remission induction therapy of ANCA-associated vasculitis.

Poster

High burden of disease for AAV patients in Germany - a claims study.

Poster

Renal damage in ANCA-associated vasculitis in incident and relapsing patients.

Slide deck

Vasculitis 2019 Workshop

Comorbidity, adverse events and infections are major concerns in real world management of ANCA-associated vasculitis.

Abstract Poster

Severity of ANCA-associated vasculitis and response to induction therapy in new and relapsing patients.

Abstract Poster

What is the ANCA-associated vasculitis community discussing online?

Abstract Poster

UK Renal week 2019

Variable response to induction therapy and significant burden of treatment adverse events over the first 12 months of remission induction treatment in ANCA-associated vasculitis patients.

Poster

EULAR 2019

Economic burden of ANCA-associated vasculitis in Germany - a claims data study.

Poster

Adverse events due to high-dose glucocorticoids - lessons from ANCA-associated vasculitis and other inflammatory diseases.

Poster

Severity and response to induction therapy in new and relapsing ANCA-associated vasculitis patients - real world practice data.

Poster

BSR 2018

Management of ANCA-associated vasculitis in the UK: a complex pathway of patient referral, diagnosis, and treatment.

Poster

ACR 2018

Variable Response to Induction Therapy and Significant Burden of Treatment Adverse Events...

Abstract Poster

Patient Experience in ANCA-Associated Vasculitis Evolves over Time from from Diagnosis...

Abstract Poster

ASN 2018

Patient Experience in ANCA-Associated Vasculitis - Challenges from Diagnosis and Need for New Approaches.

Abstract Poster

Patients with Relapsing ANCA-Associated Vasculitis (AAV) Experience Unmet Needs around Remission Induction and Therapy Related Adverse Events.

Abstract Poster

Real World Experience in ANCA-Associated Vasculitis (AAV) – A Complex Pathway of Patient Referral, Diagnosis, and Management.

Abstract Poster

Response to Induction Therapy and Treatment Adverse Events in Incident ANCA-Associated Vasculitis (AAV) Patients.

Abstract Poster

Adverse Events Due to Glucocorticoids in ANCA-Associated Vasculitis Are Frequent but Reporting Should Improve.

Abstract Poster

Patient Support Organisations

Vasculitis International
Vasculitis International
Europe
www.vasculitis.eu
Selbsthilfe Vaskulitis e.V.
Selbsthilfe Vaskulitis e.V.
Germany
www.vaskulitisverein-rlp.de
Associazione Pazienti della Sindrome di Churg Strauss
Associazione Pazienti della Sindrome di Churg Strauss
Italy
www.apacs-egpa.org
Suomen Vaskuliittiyhdistys ry
Suomen Vaskuliittiyhdistys ry
Finland
www.vaskuliittiyhdistys.fi
Selbsthilfe Vaskulitis Mainz
Selbsthilfe Vaskulitis Mainz
Germany
vaskulitis-mainz@gmx.de
Vasculitis Stichting
Vasculitis Stichting
Netherlands
www.vasculitis.nl
Association Vascularites
Association Vascularites
France/Belgium
www.association-vascularites.org
Vasculitis Ireland
Vasculitis Ireland
Ireland
www.vasculitis-ia.org
Vasculitis UK
Vasculitis UK
United Kingdom
www.vasculitis.org.uk
Vifor Renal Pharma footer logo

This website is educational, non-promotional and intended for healthcare professionals practicing outside of the United States.
For more information contact medinfo@viforpharma.com. HQ-AVA-2000105 / Last updated: November 2020

twitter